{"transactions":[{"id":885061,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Head of R&D"}}],"security":"Common Stock","published_at":"2026-02-25T01:53:37.000Z","date":"2026-02-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":338282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the \"Closing Date\"), with 338,282 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 338,282 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the \"Closing Date\"), with 338,282 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 338,282 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture."}],"balance_after":676564,"source":{"system":"sec-edgar","filing":"0001193125-26-068077","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526068077/ownership.xml","form_type":"4"}},{"id":944555,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T21:21:52.000Z","date":"2026-01-05","kind":"grant","planned":false,"acquired":true,"shares":900117,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date."}],"balance_after":900117,"derivative":{"exercise_price":2.01,"expiration_date":"2036-01-05","underlying":"Common Stock","underlying_shares":900117},"source":{"system":"sec-edgar","filing":"0001193125-26-006350","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526006350/ownership.xml","form_type":"4"}},{"id":1095291,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T00:00:09.000Z","date":"2025-02-21","kind":"grant","planned":false,"acquired":true,"shares":1100705,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported an incorrect exercise price with respect to the stock option award originally granted on February 21, 2025. This amendment is being filed solely to correct the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in three substantially equal installments on the second, third and fourth anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date."}],"balance_after":1100705,"derivative":{"exercise_price":2.97,"expiration_date":"2035-02-21","underlying":"Common Stock","underlying_shares":1100705},"source":{"system":"sec-edgar","filing":"0000950170-25-093445","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025093445/ownership.xml","form_type":"4/A","original_submission_date":"2025-02-25"}},{"id":1246367,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-25T21:10:05.000Z","date":"2025-02-21","kind":"grant","planned":false,"acquired":true,"shares":1100705,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in three substantially equal installments on the second, third and fourth anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date."}],"balance_after":1100705,"derivative":{"exercise_price":2.23,"expiration_date":"2035-02-21","underlying":"Common Stock","underlying_shares":1100705},"source":{"system":"sec-edgar","filing":"0000950170-25-026652","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025026652/ownership.xml","form_type":"4"}},{"id":1882810,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & Head of R&D"}}],"security":"Class A Ordinary Shares","published_at":"2023-05-23T01:15:56.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":162060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted an award of 162,060 Restricted Share Units (\"RSUs\") on May 18, 2023 (the \"Grant Date\"). Under the terms of the RSU grant, 25% of the RSUs vest on each of the anniversaries of the Grant Date, such that the RSUs vest equally over four years, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":162060,"source":{"system":"sec-edgar","filing":"0001104659-23-063312","document":"tm2316481-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923063312/tm2316481-2_4seq1.xml","form_type":"4"}},{"id":2041852,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-30T21:05:43.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":1700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan."}],"balance_after":1700,"derivative":{"exercise_price":3.99,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":1700},"source":{"system":"sec-edgar","filing":"0001493152-23-002919","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223002919/ownership.xml","form_type":"4"}},{"id":2420869,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-31T14:36:17.000Z","date":"2022-01-27","kind":"grant","acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 27, 2022, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan."}],"balance_after":22100,"derivative":{"exercise_price":0.3701,"expiration_date":"2032-01-27","underlying":"Common Stock","underlying_shares":22100},"source":{"system":"sec-edgar","filing":"0001493152-22-002676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222002676/ownership.xml","form_type":"4"}},{"id":2888266,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-02T02:45:47.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan."}],"balance_after":15000,"derivative":{"exercise_price":1.47,"expiration_date":"2031-01-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-21-002328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315221002328/ownership.xml","form_type":"4"}},{"id":2964608,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D, and CMO"}}],"security":"Performance Restricted Stock Unit","published_at":"2020-11-30T16:01:24.000Z","date":"2020-11-25","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 5,000 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 2,500 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 2,500 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 5,000 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 5,000 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 2,500 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 2,500 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 5,000 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 5,000 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 2,500 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 2,500 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 5,000 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The amount reported in Column 7 of Table II represents the common shares that vested on November 25, 2020. The PRSUs' final Closing Price target has been met and the Reporting Person has a contingent right to receive 5,000 additional common shares if the subsequent continuing service requirement is met."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 5,000 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 2,500 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 2,500 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 5,000 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement."}],"balance_after":5000,"derivative":{"expiration_date":"2022-01-03","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-20-060721","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120060721/doc4.xml","form_type":"4"}},{"id":2964607,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D, and CMO"}}],"security":"Common Stock","published_at":"2020-11-30T16:01:24.000Z","date":"2020-11-25","kind":"tax_withholding","acquired":false,"shares":1099,"price":65.5,"value":71984.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the PRSUs."}],"balance_after":1401,"source":{"system":"sec-edgar","filing":"0001209191-20-060721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120060721/doc4.xml","form_type":"4"}},{"id":2964606,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D, and CMO"}}],"security":"Common Stock","published_at":"2020-11-30T16:01:24.000Z","date":"2020-11-25","kind":"exercise","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 5,000 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 2,500 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 2,500 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 5,000 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001209191-20-060721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120060721/doc4.xml","form_type":"4"}},{"id":3080995,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D, and CMO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-07-17T17:23:38.000Z","date":"2020-07-15","kind":"exercise","acquired":false,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest over four years, with 25% of the shares subject to the option vesting on November 15, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":47000,"derivative":{"exercise_price":26.28,"expiration_date":"2024-11-15","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001209191-20-042910","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120042910/doc4.xml","form_type":"4"}},{"id":3080994,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D, and CMO"}}],"security":"Common Stock","published_at":"2020-07-17T17:23:38.000Z","date":"2020-07-15","kind":"sale","acquired":false,"shares":13000,"price":68,"value":884000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-042910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120042910/doc4.xml","form_type":"4"}},{"id":3080993,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D, and CMO"}}],"security":"Common Stock","published_at":"2020-07-17T17:23:38.000Z","date":"2020-07-15","kind":"exercise","acquired":true,"shares":13000,"price":26.28,"value":341640.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":13000,"source":{"system":"sec-edgar","filing":"0001209191-20-042910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120042910/doc4.xml","form_type":"4"}},{"id":3099545,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-26T01:46:11.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4) of the shares underlying this stock option will vest and become exercisable on the first anniversary of the date of grant, and an additional 2.083% of the shares underlying this option will vest on the last day of each of the thirty-six (36) months that follow the first anniversary of the date of grant, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan."}],"balance_after":30000,"derivative":{"exercise_price":1.95,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-20-011850","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315220011850/ownership.xml","form_type":"4"}},{"id":3109513,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":64958,"kind":"person","name":"Cabell Christopher","position":1,"cik":"0001814928","reported_name":"Cabell Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D, and CMO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-06-16T19:25:55.000Z","date":"2020-06-12","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over four years, with 25% of the shares subject to the option vesting on June 12, 2021, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":20000,"derivative":{"exercise_price":61.31,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-20-037092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120037092/doc4.xml","form_type":"4"}}]}